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FeatureUK research councils have drawn up a strategic plan for the development of 
regenerative medicine, covering all aspects from basic research through to 
commercialisation. Michael Gross reports. 
A roadmap for regenerative medicineStem cells: Researchers working with stem cells at the James Martin 21st Century School in 
Oxford. (Photo: William James.)Recent years have seen dramatic 
progress in the production and 
understanding of pluripotent cells, 
which, researchers hope, will 
ultimately provide the option of 
creating replacement cells, tissues 
or organs in the laboratory. There 
are currently three potential access 
routes to such cell therapies, 
including embryonic stem cells, 
induced pluripotent cells, and 
transdifferentiated cells (Curr. Biol. 
(2011), 21, R235–R237).
However, challenges remain both 
in the fundamental science and 
in its translation to the clinic. The 
UK’s Medical Research Council 
(MRC), together with other research 
councils and the government’s 
Technology Strategy Board (TSB), 
has now outlined a detailed strategy 
suggesting what UK agencies and 
researchers should do over the next 
five years in order to retain their 
leading role in this field and drive it 
towards clinical application. 
The forward-looking report, titled 
“A strategy for UK regenerative 
medicine” (http://www.mrc.ac.uk/
Newspublications/News/MRC008536), 
builds on a previous government 
report taking stock of past and 
current developments in the field, an 
analysis of investment and funding 
streams, and the outcomes of a “key 
opinion leaders workshop” held last 
September. 
What to do
The workshop, which involved 
active researchers, clinicians and 
representatives from industry and 
funding agencies, was a kind of 
brainstorming, as one participant 
recalls it, and produced a preliminary 
summary which provided the eight 
main themes that are the backbone of 
the new strategy paper. 
There are five themes spanning 
the natural course of R&D 
from basic research through to 
commercialisation, and another three 
overarching ones dealing with general 
issues such as interdisciplinarity and international competition and 
collaboration. 
At the research front, where the 
UK already has established a strong 
position built on earlier pioneering 
achievements, including IVF and 
the cloning of Dolly the sheep, the 
report names a number of “drivers”, 
which “include a need to increase 
our understanding of cellular 
reprogramming, differentiation and 
ageing, disease and reparative 
mechanisms, stem cell niches, the 
extracellular environment, genetic 
instability, of how we harness 
the immune response, advanced 
bioprocessing, and undertake 
predictive modelling of innovation 
and value systems.” Funding for 
this research will continue to be 
made available, the report promises: “Support for such investigations will 
be provided through response mode 
funding, and continued strategic 
investment in centres of excellence 
and partnerships with industry.”
A £25m cross-council UK 
Regenerative Medicine Platform 
(UKRMP) is now accepting grant 
applications. It will also work closely 
with the TSB’s “Catapult Centre Cell 
Therapy” set up at the end of last year. 
“We welcome the UK government’s 
continued commitment to 
regenerative medicine and the 
balance it has struck between basic 
and translational research,” says 
Paul Fairchild, a director of the 
Oxford Stem Cell Institute of the 
James Martin 21st Century School. 
“While we still need to do more work 
to address fundamental issues, 
such as the mechanisms of cellular 
reprogramming and ways of pacifying 
the immune response to replacement 
tissues, the anticipated benefits 
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Regeneration rules: Salamanders can regenerate lost limbs even as adults, probably due to 
an ability to reprogram adult cells to a pluripotent state and then repeating the limb develop-
ment. Researchers hope to develop methods of regenerating human tissues and organs from 
reprogrammed or stem cells within the next few years. (Photo courtesy of Elly Tanaka.)to human health demand a strong 
emphasis on translational aspects and 
on bringing therapies to the clinic.”
Fairchild’s group has recently 
succeeded in producing human 
dendritic cells from induced 
pluripotent stem cells (iPS cells) using 
protocols that would be compatible 
with clinical applications. The 
underlying idea is that dendritic cells 
derived from the same source as a 
transplanted tissue or cell population 
would induce the recipient’s immune 
system to accept the transplant 
as ‘self’ (Gene Therapy (2011) doi: 
10.1038/gt.2011.177). 
Considering the various therapeutic 
options to which stem cell research 
may translate, the report states that 
“given uncertainties regarding the 
efficacy and safety of these different 
approaches, it will be important to 
maintain studies of all”. The logical 
next step is product development, 
which will also benefit from funding 
from the UKRMP and from the TSB’s 
Catapult Centre. As methods in tissue 
engineering advance, growing tube-
shaped organs such as the urethra 
in the lab is becoming feasible, while 
solid organs such as heart and liver 
are still out of reach. Once developed, 
cell therapies and replacement organs 
need to be clinically evaluated. There 
are intrinsic challenges in the process 
when it applies to living materials, as 
opposed to molecular agents, as cell cultures are much more difficult to 
standardise and may mutate over time. 
So far, first-in-man and early phase 
clinical trials of regenerative medicine 
therapies are scarce, warns Martin 
Birchall from the Ear Institute at 
University College London, especially 
those with reasonable follow-up on 
which to base phase III studies and 
commercialisation. Birchall carried 
out the first stem cell transplant of 
a windpipe in 2008, pioneering a 
technique that involves stripping 
a donor organ of its own cells and 
repopulating the remaining protein 
scaffold with stem cells from the 
recipient. He is now working on the 
application of similar methods to 
the repair of the voice box (larynx), 
with clinical trials expected to begin 
in 2013. “The recent brainstorming 
session involving the UK RM 
community determined key areas 
where science had not caught up with 
our translational aspirations. These 
are those highlighted in the present 
call,” he says. 
“Clinicians have identified a wide 
array of unmet patient needs, and 
academic clinicians are trying to 
put putative regenerative medicine 
solutions through early phase 
clinical trials. Developing the areas 
highlighted here will help,” Birchall 
acknowledges. However, he warns, 
“there remains a huge pre-clinical 
trial application and clinical good manufacturing practice capacity 
gap in the UK which will need to 
be urgently bridged if the early 
phase trials that will be lifeblood 
of the UKRM Catapult are actually 
going to deliver. Both areas (limiting 
technologies, and capacity) need 
addressing urgently, but this present 
call is an important step towards the 
first of these.”
In the last step of the strategy, the 
products have to be commercialised 
to secure industrial production and 
delivery to the clinic. Given the 
fundamental differences between 
cell therapies and conventional drug 
therapies, the report acknowledges 
that new business models may be 
required, and that funding may be 
necessary to get this development 
started. 
How to do it 
The remaining three strategic themes 
of the report are covering general 
aspects of how to do the work. 
Developments should focus on clearly 
defined medical targets, the report 
suggests. Therefore, “the sponsors 
will work, in a second phase of the 
UKRMP initiative, to identify key 
disease areas/therapy types meriting 
concerted investment, and will work 
with other interested funders to 
develop mechanisms to capture these 
opportunities.”
Then, like many other areas of 
leading edge research too, the work 
has to be interdisciplinary to be 
successful. In this respect, the report 
merely states the obvious, namely 
that people have to communicate 
with each other and funding 
organisations try to help them with 
the networking. The problems arising 
from the separate cultures found 
in relevant disciplines, such as 
clinical medicine and engineering, 
are only acknowledged in passing, 
as the report states that, while the 
community expressed the wish for 
more interdisciplinary working, “there 
exist community-based hurdles to 
its formation, including the challenge 
of establishing a common language 
between disciplines and defining 
shared and valued goals.” It doesn’t 
suggest specific solutions that 
might bridge the gaps between the 
disciplines concerned. 
Finally, while the report is mainly 
concerned with the R&D in the 
UK, it also has to acknowledge 
the importance of international 
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Vatican views: The Catholic church is among the organisations with the strongest objections 
against the use of human embryonic stem cells for research into regenerative medicine. The 
photo shows the Vatican and St. Peter’s Basilica in Rome. (Photo: Wikimedia Commons.)
Ottoline Leyser
Ottoline Leyser graduated with a 
BA in Genetics from the University 
of Cambridge in 1986. As an 
undergraduate, she was inspired by 
an interdepartmental developmental 
biology course, which highlighted for 
her the power of genetic approaches, 
and the extent to which plant 
developmental biology was lagging 
behind, at least in part through the 
lack of a really tractable genetic 
model system. Fortunately, it was 
exactly at this time that Arabidopsis 
began its exponential rise as a model 
for plant developmental genetics, 
and she stayed in the Cambridge 
Genetics Department to pursue a PhD 
on Arabidopsis shoot apical meristem 
mutants with Ian Furner. After a post-
doc in Bloomington, Indiana with 
Mark Estelle studying auxin mutants, 
eventfully punctuated by the births 
of her two children, and a brief spell 
back in Cambridge, she moved to 
the University of York. There, she 
established a research project on the 
hormonal control of shoot branching, 
which has been the focus of her 
research ever since. Last year she 
took up a new post as Professor of 
Plant Development and Associate 
Director of the Sainsbury Laboratory 
at the University of Cambridge. 
What turned you on to biology in 
the first place? I like to understand 
how things work, and, to my mind, 
living systems are really the most 
interesting to understand, because 
they were built by evolution. This 
makes their logic often non-intuitive 
and means that their organisation 
is inherently multi-scale, with the 
properties of the whole organism, 
or indeed whole ecosystems, both 
emerging from and in turn influencing 
the interactions of component 
parts at multiple successive 
lower-level scales. This is the 
reason I find genetics particularly 
appealing — because it affords us the 
extraordinary ability to link specific 
and informative macro-scale changes 
to single nucleotide DNA-level 
changes. These techniques powerfully 
link genotype to phenotype, but the 
challenge then is to work out the 
steps in between. 
Q & Acompetition and collaboration. 
Research elsewhere is simultaneously 
described as a threat and an 
opportunity. To make the most of the 
latter, “the sponsors will work with 
overseas partners through established 
long-term relationships and new 
partnerships to capitalise upon 
emerging opportunities and provide 
access to complementary expertise 
that will benefit UK science,” the 
report states.
Oxford’s Paul Fairchild comments: 
“Recent initiatives to foster 
collaboration between UK scientists 
and those in countries such as Israel 
and China with a strong background in 
regenerative medicine is likely to 
bring a new perspective to the field 
and stimulate promising new avenues 
of research. The availability of new 
funding streams for joint projects 
between laboratories is particularly 
welcome.”
Around the world
A look around the globe continues 
to show a very colourful tapestry 
of different cultural attitudes to 
stem cell research and thus to the 
options of regenerative medicine. For 
instance, researchers in Germany are 
still banned from producing human 
embryonic stem cells and can only 
use imported cell lines if they were 
produced before 1st May 2007. In 
the US, opinions are divided and 
regulations differ between states, 
while countries such as Israel and South Korea enthusiastically support 
stem cell research. 
The debate over ethical concerns 
raised especially by the Christian 
churches has recently been 
highlighted, when the Vatican’s 
scientific academy cancelled a 
conference on adult stem cells that 
was due to be held at the end of 
April. The organiser’s brief to focus 
on “responsible stem cell research”, 
i.e. to exclude research on embryonic 
stem cells, had already divided the 
research community, with some 
scientists accepting the invitation, 
while others called to boycott the 
event. 
On the other side of the debate, the 
fact that some of the invited speakers, 
including keynote speaker George 
Daley from the Children’s Hospital at 
Boston (Massachusetts), are famous 
for their work with embryonic stem 
cells, produced disquiet among 
the members of the Pontifical 
Academy for Life, which organised 
the event. While the academy cited 
organisational reasons for the 
cancellation, internal debate on the 
choice of speakers may conceivably 
have had something to do with it. 
Which would be ironic, because today, 
more than ever, regenerative medicine 
has a range of options beyond the use 
of embryonic stem cells. 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web 
page at www.michaelgross.co.uk
